Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Kezar Life Sciences Inc (DE:2KZ)
FRANKFURT:2KZ
RESEARCH TOOLSreports
Holding DE:2KZ?
Track your performance easily
2KZ Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.42 - €1.20
Previous Close€0.48
Volume0.00
Average Volume (3M)N/A
Market Cap
€37.94M
Enterprise Value-€94.24M
Total Cash (Recent Filing)$164.18M
Total Debt (Recent Filing)$17.61M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 07, 2024EPS Estimate
-€0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding72,962,220
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.21
Price to Sales (P/S)5.99
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-13.46
Enterprise Value/Gross Profit-13.46
Enterprise Value/Ebitda0.98
Forecast
1Y Price Target
€4.06Price Target Upside745.80% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Kezar Life Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEarly completion of enrollment for Zeto's Phase 2 PORTOLA trial in autoimmune hepatitis indicates high unmet need and treatment demand.
Operational EfficiencyWorkforce reduction of 41% in 4Q23 extends cash runway into late 2026, ensuring financial stability beyond all key topline readouts.
Strategic PartnershipsExclusive licensing agreement with Everest Medicines to develop and commercialize zeto in Greater China, South Korea, and Southeast Asia boosts market expansion potential.
Bears Say
Clinical TrialsKZR-261's enrollment has stopped due to no responses seen in the study, only stable disease.
Financial PerformanceThe company ended 2Q24 with $165MM in cash, and if the current level of cash burn continues, the company may face funding challenges by 2H26.
Market DynamicsAdjusting the discount rate to 15% from 10% to reflect the increasing volume of companies entering the competitive development arena with respect to the systemic lupus erythematosus (SLE) and lupus nephritis (LN) indications.
---
Options Prices
Currently, No data available
---
Ownership Overview
21.77% Insiders
13.06% Mutual Funds
37.51% Other Institutional Investors
27.66% Public Companies and
Individual Investors
2KZ FAQ
What was Kezar Life Sciences Inc’s price range in the past 12 months?
Kezar Life Sciences Inc lowest stock price was €0.42 and its highest was €1.20 in the past 12 months.
What is Kezar Life Sciences Inc’s market cap?
Currently, no data Available
When is Kezar Life Sciences Inc’s upcoming earnings report date?
Kezar Life Sciences Inc’s upcoming earnings report date is Nov 07, 2024 which is in 49 days.
How were Kezar Life Sciences Inc’s earnings last quarter?
Kezar Life Sciences Inc released its earnings results on Aug 13, 2024. The company reported -€0.271 earnings per share for the quarter, beating the consensus estimate of -€0.289 by €0.018.
Is Kezar Life Sciences Inc overvalued?
According to Wall Street analysts Kezar Life Sciences Inc’s price is currently Undervalued.
Does Kezar Life Sciences Inc pay dividends?
Kezar Life Sciences Inc does not currently pay dividends.
What is Kezar Life Sciences Inc’s EPS estimate?
Kezar Life Sciences Inc’s EPS estimate is -€0.28.
How many shares outstanding does Kezar Life Sciences Inc have?
Kezar Life Sciences Inc has 72,962,220 shares outstanding.
What happened to Kezar Life Sciences Inc’s price movement after its last earnings report?
Kezar Life Sciences Inc reported an EPS of -€0.271 in its last earnings report, beating expectations of -€0.289. Following the earnings report the stock price went down -2.178%.
Which hedge fund is a major shareholder of Kezar Life Sciences Inc?
Among the largest hedge funds holding Kezar Life Sciences Inc’s share is Wexford Capital LP. It holds Kezar Life Sciences Inc’s shares valued at N/A.
---
Kezar Life Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€4.06 (745.80% Upside)
€4.06 (745.80% Upside)
Blogger Sentiment
Bullish
DE:2KZ Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.78%
12-Months-Change
Fundamentals
Return on Equity
-51.48%
Trailing 12-Months
Asset Growth
-31.69%
Trailing 12-Months
Company Description
Kezar Life Sciences Inc
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
---
2KZ Stock 12 Month Forecast
Average Price Target
€4.06
▲(745.80% Upside)
Technical Analysis
Bioxcel Therapeutics
―
Corbus Pharmaceuticals
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Kezar Life Sciences
―
Best Analysts Covering 2KZ
1 Year
1 Year Success Rate
4/15 ratings generated profit
1 Year Average Return
-20.83%
assigned a buy rating last month
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -20.83% per trade.
---